NEW YORK (GenomeWeb) – Thermo Fisher Scientific said during its analyst day last week that it plans to launch a walkaway mass spectrometry-based clinical analyzer in 2018.

The announcement confirmed previous reports that the company was working on such an instrument, though it provided little information on what types of assays or molecules the analyzer might target, and it declined to comment further on its plans for the instrument.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.